2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AssigneesIdenix Pharmaceuticals, Inc., University of Cagliari, Centre National De La Recherche Scientifique, L'Universite Montpellier II
InventorsJean-Pierre Sommadossi, Paolo LaColla, Gilles Gosselin
Life of this patent
Estimating the term…
Abstract
The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
Claims36
A method of treating a host infected with a Flaviviridae virus, comprising administering to the host an effective amount of a compound having the structure of the formula:
- or a pharmaceutically acceptable salt or prodrug thereof optionally in a pharmaceutically acceptable carrier.
A method for treating a host infected with an RNA-dependant RNA polymerase virus, comprising administering an effective amount of the compound of the formula:
- or its mono or dihydrochloride in pharmaceutically acceptable carrier, wherein the 5′-hydroxyl group is replaced with a 5′-OR, wherein R is hydrogen, phosphate;
- a stabilized phosphate prodrug;
- acyl;
- an amino acid;
- a carbohydrate;
- a peptide;
- or other pharmaceutically acceptable leaving group which when administered in viva provides a compound wherein R is independently H or phosphate.
Dependencies are inferred from the claim text.